BVBiomedical Ltd is pleased to announce that it has entered into the pre-IND phase with the FDA on Nuevene™. A key milestone in the development of our treatment hoping to bring relief to millions of suffers.
News
Recent News
BVBiomedical Ltd was awarded a grant from the SIGHT programme for corporate development (https://www.sightprogramme.co.uk/).
BVBiomedical Ltd and DyoDelta Biosciences Ltd, London, entered into a collaboration for the commercialization of Neuvene™ in treating MS and CTE.
BVBiomedical Ltd entered into a collaboration with The Florey Institute, Victoria, Australia for pre-clinical development of the relaxin variant B7-33 for the treatment of MS and CTE.
BVBiomedical Ltd entered into a collaboration with Innovate UK EDGE, The national innovation & growth service for ambitious businesses (www.innovateukedge.ukri.org).
Australian Patent No. 2016320544 in the name of BVBiomedical Limited For a Novel Therapy was granted.
United States Patent No. 11344607 in the name of BVBiomedical Limited For a Novel Therapy was granted.
BVBiomedical Ltd entered into a collaboration with Cognition Health, London to develop a clinical trial protocol for the use of relaxin to treat CTE in retired rugby players.
BVBiomed is a research driven company dedicated to the discovery of novel therapeutic compounds for use in treating neuro-degenerative diseases. We are currently developing two new compounds which are anti-inflammatory and auto-immune regulators and are preparing clinical trials of these therapies in treating multiple sclerosis.
Contacts
-
- Address
- Magdalen Centre, The Oxford Science Park, Robert Robinson Drive, Oxford, Oxfordshire OX4 4GA, U.K.
-
- Phone
-
- +44 1865 784 062
-
- info [at] bvbiomed . com
(remove spaces between words)